Werewolf Therapeutics to Present at Upcoming Next-Gen Cytokine Therapeutics Summit

Rhea-AI Summary

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) will present at the Next-Gen Cytokine Therapeutics Summit on September 22, 2021. Chief Scientific Officer, Cynthia Seidel-Dugan, Ph.D., will discuss advancements in cytokine therapeutics at 4:20 PM EDT, followed by Chief Medical Officer, Randi Isaacs, M.D., on a panel discussing the future of cytokine therapies at 4:50 PM EDT. The company focuses on innovative therapeutics that leverage its proprietary PREDATOR™ platform to enhance cancer treatment through conditionally activated INDUKINE™ molecules.

CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that members of its leadership team will present at the Next-Gen Cytokine Therapeutics Summit on September 22.

Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf, will deliver a presentation entitled, “Pioneering the Development of Therapeutics Engineered to Overcome Key Challenges and Unlock the Full Potential of Cytokine Therapeutics,” at 4:20 pm EDT on September 22.

Following Dr. Seidel-Dugan’s presentation, Werewolf’s Chief Medical Officer, Randi Isaacs, M.D., will participate in a Summit panel discussion at 4:50 pm EDT entitled, “Where does the Future Lie for Cytokine Therapies?” More information on attending the Summit can be found at https://www.cytokinetherapeutics.com/.

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit www.werewolftx.com.

Investor Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com 

FAQ

What is Werewolf Therapeutics presenting at the Next-Gen Cytokine Therapeutics Summit on September 22, 2021?

Werewolf Therapeutics will present advancements in cytokine therapeutics at the Next-Gen Cytokine Therapeutics Summit.

Who is presenting at the Next-Gen Cytokine Therapeutics Summit for Werewolf Therapeutics?

Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer, will present, followed by Randi Isaacs, M.D., Chief Medical Officer.

What time is Cynthia Seidel-Dugan's presentation at the summit?

Cynthia Seidel-Dugan's presentation is scheduled for 4:20 PM EDT on September 22, 2021.

What topic will Randi Isaacs discuss at the summit?

Randi Isaacs will participate in a panel discussion on the future of cytokine therapies at 4:50 PM EDT.

What is the stock symbol for Werewolf Therapeutics?

The stock symbol for Werewolf Therapeutics is HOWL.